Search
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data).
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Trofinetide
go.drugbank.com/drugs/DB06045ApprovedTrofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor … [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union.
Synonyms: glycyl-L-2-methylprolyl-L-glutamic acidTrimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesMaftivimab
go.drugbank.com/drugs/DB15899ApprovedInvestigational(i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalOlodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. … Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing.
Bitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Synonyms: Human botulinum neurotoxin A/B immune globulin, Botulism immune globulin IV human